Osimertinib and chemotherapy combination to treat brain metastasis flare and osimertinib resistance by EGFR C797S

References

• Soria J-C, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–125. Jan
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629–640. Feb
   PubMed Web of Science ®Google Scholar
• Lee J, Choi Y, la Han J, et al. Osimertinib improves overall survival in patients with EGFR-Mutated NSCLC with leptomeningeal metastases regardless of T790M mutational status. J Thorac Oncol. 2020;15(11):1758–1766. Nov
   PubMed Web of Science ®Google Scholar
• Ballard P, Yates JWT, Yang Z, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22(20):5130–5140.
   PubMed Web of Science ®Google Scholar
• Pareek V, Welch M, Ravera E, et al. Marked differences in CNS activity among EGFR inhibitors: case report and mini-review. J Thorac Oncol. 2016;11(11):e135–e139.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Cheng Y, Zhou C, et al. Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. Ann Oncol. [Internet]2018;29:viii740. Oct 1Available
   PubMedGoogle Scholar
• Papadimitrakopoulou VA, Wu Y-L, Han J-Y, et al. Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study. Ann Oncol. 2018;29:viii741.
   Web of Science ®Google Scholar
• Oxnard GR, Hu Y, Mileham KF, et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. JAMA Oncol. 2018;4(11):1527–1534. Nov 1
   PubMed Web of Science ®Google Scholar
• Leonetti A, Sharma S, Minari R, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121(9):725–737.
   PubMed Web of Science ®Google Scholar
• Le X, Puri S, Negrao M V, et al. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. Clin Cancer Res. 2018;24(24):6195–6203.
   PubMed Web of Science ®Google Scholar
• Lee CK, Man J, Lord S, et al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis. J Thorac Oncol. 2017;12(2):403–407. Feb
   PubMed Web of Science ®Google Scholar
• Yoshida H, Ooi M, Kim YH. Successful treatment with osimertinib and chemotherapy in a non-small cell lung cancer patient with EGFR mutation and meningeal carcinomatosis. J Thorac Oncol. 2018;13(11):e219–e220.
   PubMed Web of Science ®Google Scholar
• Cortellini A, Leonetti A, Catino A, et al. Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes. Clin Transl Oncol. 2020 Jun 7;22(6):844–851.
   PubMed Web of Science ®Google Scholar
• Bauml J, Cho BC, Park K, et al. Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. J Clin Oncol. 2021;39(15_suppl):9006–9006.
   Web of Science ®Google Scholar
• Sequist LV, Han J-Y, Ahn M-J, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020;21(3):373–386. Mar
   PubMed Web of Science ®Google Scholar
• Jia Y, Yun C-H, Park E, et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature. 2016;534(7605):129–132.
   PubMed Web of Science ®Google Scholar
• Janne PA, Baik CS, Su W-C, et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). J Clin Oncol. 2021;39(15_suppl):9007–9007.
   Web of Science ®Google Scholar
• Riely GJ, Kris MG, Zhao B, et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res. 2007;13(17):5150–5155.
   PubMed Web of Science ®Google Scholar
• Chaft JE, Oxnard GR, Sima CS, et al. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res. 2011;17(19):6298–6303.
   PubMed Web of Science ®Google Scholar
• Chen H-J, Yan H-H, Yang J-J, et al. Disease flare after EGFR tyrosine kinase inhibitor cessation predicts poor survival in patients with non-small cell lung cancer. Pathol Oncol Res. 2013;19(4):833–838. Oct
   PubMed Web of Science ®Google Scholar
• Kunimasa K, Mimura C, Kotani Y. Erlotinib is effective for leptomeningeal carcinomatosis due to disease flare after osimertinib treatment failure. J Thorac Oncol. 2017;12(7):e93–e94.
   PubMedGoogle Scholar
• Takahashi T, Umeguchi H, Tateishi A, et al. Disease flare of leptomeningeal metastases without radiological and cytological findings after the discontinuation of osimertinib. Lung Cancer. 2021;151:1–4.
   PubMed Web of Science ®Google Scholar
• Kim YH, Fukuhara A, Mishima M. Should epidermal growth factor receptor-tyrosine kinase inhibitor be continued beyond progressive disease? Case Rep Oncol. 2011;4(3):470–474.
   PubMedGoogle Scholar
• Noronha V, Patil VM, Joshi A, et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-Mutated lung cancer. J Clin Oncol. 2020;38(2):124–136. Jan
   PubMed Web of Science ®Google Scholar
• White MN, Piotrowska Z, Stirling K, et al. Combining osimertinib with chemotherapy in EGFR-Mutant NSCLC at progression. Clin Lung Cancer. 2021;22(3):201–209.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Asahina H, Kishimoto J, et al. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: an open-label, randomised phase 2 clinical trial. Eur J Cancer. 2021;149:14–22.
   PubMed Web of Science ®Google Scholar
• Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21(6):560–562. https://pubmed.ncbi.nlm.nih.gov/25939061
   PubMed Web of Science ®Google Scholar
• Niederst MJ, Hu H, Mulvey HE, et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment Strategies. Clin Cancer Res. 2015;21(17):3924–3933. Sep 1
   PubMed Web of Science ®Google Scholar
• Wang Q, Yang S, Wang K, et al. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J Hematol Oncol. 2019;12(1):63.
   PubMedGoogle Scholar
• Jacus MO, Daryani VM, Harstead KE, et al. Pharmacokinetic properties of anticancer agents for the treatment of Central nervous system tumors: Update of the literature. Clin Pharmacokinet. 2016;55(3):297–311.
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Cantarini M, Frewer P, et al. SAVANNAH: a phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET -driven (MET +), locally advanced or metastatic non-small cell lung cancer (NSCLC), following disease progression on osimertinib. J Clin Oncol. 2019;37(15_suppl):TPS9119–TPS9119.
   Web of Science ®Google Scholar
• Yang JC-H, Ellers-Lenz B, Straub J, et al. INSIGHT 2: tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: a phase II trial in progress study. Ann Oncol. 2019;30:ix181.
   Web of Science ®Google Scholar